Invivyd (IVVD) News Today

Shares of Invivyd, Inc. (NASDAQ:IVVD) have edged lower amid a mix of financing, analyst updates and insider activity. Key developments for investors:

• Positive Sentiment: Invivyd closed its $57.5 million underwritten public offering—including full exercise of the underwriter’s option—at $0.52 per share, strengthening its cash runway for clinical and corporate initiatives. Invivyd Announces Closing of $57.5 Million Public Offering…
• Positive Sentiment: Top healthcare investors RA Capital Management and Janus Henderson Investors led the financing round, signaling strong institutional confidence in Invivyd’s strategy. Invivyd, Inc. Closes Public Offering Raising…
• Positive Sentiment: Net proceeds will fund key programs including the VYD2311 clinical trial, RSV and measles research, and SPEAR studies on Long COVID and post-vaccination syndromes. Invivyd, Inc. Closes Public Offering Raising…
• Neutral Sentiment: On August 20, Invivyd entered into an underwriting agreement with Cantor Fitzgerald to raise $53.5 million via a public offering. Invivyd Raises $53.5 Million in Public Offering
• Neutral Sentiment: HC Wainwright updated its long-term outlook, issuing a FY2028 EPS forecast of $0.13 per share for Invivyd. FY2028 Earnings Forecast for Invivyd Issued By HC Wainwright
• Negative Sentiment: Analysts at HC Wainwright cut their Q3 2025 EPS estimate to ($0.08), reflecting softer near-term profitability expectations. HC Wainwright Analysts Cut Earnings Estimates for Invivyd
• Negative Sentiment: Shares dipped after Invivyd priced approximately $50 million in new securities at $0.52 per share, stoking dilution concerns. Invivyd Stock Falls After Pricing Capital Raise of $50M…
• Negative Sentiment: Multiple insiders—including the CFO, CSO and CCO—sold significant blocks of stock (reducing individual stakes by 18–37%), which may signal profit-taking. Insider Selling: Invivyd Insider Sells 18,512 Shares of Stock